Table 2.
Transplant recipient characteristics.
| Factor | Lower-risk (N = 21) | Higher-risk (N = 23) | P-value |
|---|---|---|---|
| Age at HSCT, median (range) | 42 (22–49) | 44 (19–50) | 0.182 |
| Sex (male), n (%) | 11 (52.4) | 14 (60.9) | 0.761 |
| FAB classification, n (%) | 0.152 | ||
| RA | 15 (71.4) | 8 (34.8) | |
| RARS | 1 (4.8) | 1 (4.3) | |
| RAEB | 3 (14.3) | 6 (26.1) | |
| RAEB-t | 1 (4.8) | 4 (17.4) | |
| Unknown/AML | 1 (4.8) | 4 (17.4) | |
| WHO classification, n (%) | 0.147 | ||
| SLD | 0 (0.0) | 2 (8.7) | |
| MLD | 12 (57.1) | 5 (21.7) | |
| RS-MLD | 0 (0.0) | 1 (4.3) | |
| EB1 | 2 (9.5) | 3 (13.0) | |
| EB2 | 2 (9.5) | 2 (8.7) | |
| Unknown/AML | 5 (23.8) | 10 (43.5) | |
| Cytogenetic risk, n (%)* | 0.03 | ||
| Very Good | 0 (0.0) | 1 (4.3) | |
| Good | 13 (61.9) | 8 (34.8) | |
| Intermediate | 7 (33.3) | 5 (21.7) | |
| Poor | 0 (0.0) | 6 (26.1) | |
| NA | 1 (4.8) | 3 (13.0) | |
| IPSS risk, n (%) | 0.451 | ||
| Low | 4 (19.0) | 4 (17.4) | |
| Int-1 | 11 (52.4) | 7 (30.4) | |
| Int-2 | 3 (14.3) | 3 (13.0) | |
| High | 2 (9.5) | 6 (26.1) | |
| NA | 1 (4.8) | 3 (13.0) | |
| IPSS-R risk, n (%) | 0.281 | ||
| Very low | 3 (14.3) | 2 (8.7) | |
| Low | 3 (14.3) | 3 (14.3) | |
| Intermediate | 5 (23.8) | 4 (17.4) | |
| High | 7 (33.3) | 3 (14.3) | |
| Very High | 2 (9.5) | 8 (34.8) | |
| NA | 1 (4.8) | 3 (14.3) | |
| Complex karyotype, n (%) | 0 (0.0) | 4 (17.4) | 0.109 |
| RBC dependence, n (%) | 9 (42.9) | 12 (52.2) | 0.65 |
| PC dependence, n (%) | 5 (23.8) | 8 (34.8) | 0.518 |
| Performance status at HSCT, n (%) | 0.736 | ||
| 0 | 11 (52.4) | 9 (42.9) | |
| 1 | 9 (42.9) | 9 (42.9) | |
| ≧2 | 1 (4.8) | 3 (14.3) | |
| HCT-CI, n (%) | 0.037 | ||
| 0 | 12 (57.1) | 17 (73.9) | |
| 1 or 2 | 2 (9.5) | 5 (21.7) | |
| ≧3 | 7 (33.3) | 1 (4.3) | |
| HMA treatment before HSCT, n (%) | 2 (9.5) | 8 (34.8) | 0.072 |
| Cytotoxic chemotherapy before HSCT, n (%) | 9 (42.9) | 11 (47.8) | 0.771 |
| Blast in BM at HSCT, n (%) | 0.068 | ||
| < 5% | 13 (61.9) | 7 (30.4) | |
| ≧ 5% | 8 (38.1) | 16 (69.6) | |
| Conditioning regimen, n (%) | 1.000 | ||
| BU/CY | 18 (85.7) | 17 (73.9) | |
| CY/TBI 12 Gy | 1 (4.8) | 2 (8.7) | |
| FLU/BU/TBI 4 Gy | 0 (0.0) | 1 (4.3) | |
| FLU/MEL/TBI 4 Gy | 2 (9.5) | 2 (8.7) | |
| FLU/CA/CY/TBI 8 Gy | 0 (0.0) | 1 (4.3) | |
| Donor source | 0.095 | ||
| HLA-matched related | 6 (28.6) | 3 (13.0) | |
| HLA-mismatched related | 3 (14.3) | 2 (8.7) | |
| HLA-matched unrelated | 9 (42.9) | 6 (26.1) | |
| HLA-mismatched unrelated | 3 (14.3) | 8 (34.8) | |
| Cord blood | 0 (0.0) | 4 (17.4) | |
| Graft type, n (%) | 0.186 | ||
| Bone marrow | 16 (76.2) | 14 (60.9) | |
| Peripheral blood | 5 (23.8) | 5 (21.7) | |
| Cord blood | 0 (0.0) | 4 (17.4) | |
| Interval from diagnosis to HSCT, n (%) | 0.752 | ||
| < 100 days | 6 (28.6) | 8 (34.8) | |
| ≧100 days | 15 (71.4) | 15 (65.2) | |
AML acute myeloid leukemia, BM bone marrow, BU busulfan, CA cytarabine, CY cyclophosphamide, EB excess blasts, FAB French-American-British, FLU fludarabine, HCT-CI hematopoietic cell transplantation-specific comorbidity index, HMA hypomethylating agents, HLA human leukocyte antigen, HSCT hematopoietic stem cell transplantation, IPSS international prognostic scoring system, MEL melphalan, MLD multilineage dysplasia, NA not available, PC platelet concentrate, RA refractory anemia, RAEB refractory anemia with excess blasts, RARS refractory anemia with ringed sideroblasts, RBC red blood cells, RS ringed sideroblasts, SLD single lineage dysplasia, TBI total body irradiation.
*Cytogenetic risks were stratified based on the Revised International Prognostic Scoring System (IPSS-R) score22.